Article
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.
Antimicrobial agents and chemotherapy - 1 Jan 2018
Ng Teresa I, Tripathi Rakesh, Reisch Thomas, Lu Liangjun, Middleton Timothy, Hopkins Todd A, Pithawalla Ron, Irvin Michelle, Dekhtyar Tatyana, Krishnan Preethi, Schnell Gretja, Beyer Jill, McDaniel Keith F, Ma Jun, Wang Guoqiang, Jiang Li-Juan, Or Yat Sun, Kempf Dale, Pilot-Matias Tami, Collins Christine
Abstract excerpt
Glecaprevir (formerly ABT-493) is a novel hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) with pangenotypic activity. It inhibited the enzymatic activity of purified NS3/4A proteases from HCV genotypes 1 to 6 in vitro (half-maximal [50%] inhibitory concentration = 3.5 to 11.3 nM) and the replication of stable HCV subgenomic replicons containing proteases from genotypes 1 to 6 (50% effective concentration...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.